Literature DB >> 9801795

The DNA sequence specificity of hedamycin damage determined by ligation-mediated PCR and linear amplification.

M J Cairns1, V Murray.   

Abstract

The DNA sequence specificity of hedamycin damage was compared using two techniques: Ligation-mediated PCR (LMPCR) and Linear Amplification (LA). The electrophoretic mobility of LA products were made comparable with LMPCR products by using a primer with a 27 bp non-binding 5'-extension. By direct comparison of the damage intensity (as represented by each of the methods), considerable bias was found in the LMPCR system with respect to LA--resulting in the under representation of lesions with T as the base 3' to the damage site. In view of this observation some caution should be exercised in the interpretation of data for DNA damage/repair specificity derived by LMPCR. In addition the extended primer LA method used in these experiments, could be applied to generate a dideoxy sequencing ladder for analysis of LMPCR products. This would negate the need to prepare Maxam-Gilbert chemical sequencing fragments for amplification through LMPCR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9801795     DOI: 10.1080/15216549800203782

Source DB:  PubMed          Journal:  Biochem Mol Biol Int        ISSN: 1039-9712


  3 in total

1.  The effect of chromatin structure on cisplatin damage in intact human cells.

Authors:  N P Davies; L C Hardman; V Murray
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

2.  Total synthesis of indole-3-acetonitrile-4-methoxy-2-C-β-D-glucopyranoside. Proposal for structural revision of the natural product.

Authors:  Akop Yepremyan; Thomas G Minehan
Journal:  Org Biomol Chem       Date:  2012-06-12       Impact factor: 3.876

3.  Total synthesis of the antitumor natural product polycarcin V and evaluation of its DNA binding profile.

Authors:  Xiao Cai; Kevin Ng; Harmanpreet Panesar; Seong-Jin Moon; Maria Paredes; Keishi Ishida; Christian Hertweck; Thomas G Minehan
Journal:  Org Lett       Date:  2014-05-13       Impact factor: 6.005

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.